Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

20254 citationsJournal Articlegold Open Access

Authors

NCT03684785.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 13, Issue 7, pp. e011651-e011651

Field-Weighted Citation Impact: 4.38